Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases

US9265763B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Marion Hitchcock · Berlin, DE
• Anne Mengel · Berlin, DE
• Vera Pütter · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Antje Margret Wengner · Berlin, DE
• Hans Briem · Bremen, DE
• Knut Eis · Berlin, DE
• Volker Schulze · Hohen Neuendorf, DE
• Amaury Ernesto Fernandez-Montalvan · Leverkusen, DE
• Stefan Prechtl · Berlin, DE
• Simon Holton · Berlin, DE
• Jörg Fanghänel · Berlin, DE
• Philip Lienau · Berlin, DE
• Cornelia PREUSSE · Berlin, DE
• Mark Jean Gnoth · Mettmann, DE

Key dates

• Filing date: Oct 4, 2012
• Grant date: Feb 23, 2016
• Expiry date: Oct 4, 2032

Classification

• Technology area (CPC —): General

Abstract

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.